SciCann Therapeutics

SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life- threatening conditions that present a high level of unmet need.

SciCann Therapeutics holds a diversified portfolio of IP and ownerships in ventures operating in the cutting edge technology of cannabinoid science, and maintains a wide network of strategic and synergistic collaborations with leading research institutes and commercial companies in the space.

The Cannabis plant contains over 400 pharmaceutically active compounds, most of which have never been studied for their profound therapeutic effects.

Recent studies suggest that unique and synergistic cannabinoid combinations may have a high therapeutic potential in almost all diseases affecting humans, including cancer, neurodegenerative diseases, auto-immune disorders, and many more.

SciCann Therapeutics is dedicated to the discovery and development of novel and proprietary technologies in the cannabinoid space, including new therapeutic agents, drug candidates, novel cannabis genetics, personalized treatment tools and more.

SciCann Therapeutics is bridging the gap between Israel’s strong R&D capabilities in the field of cannabinoid science and Canada’s booming medical cannabis markets.

SciCann Therapeutics is collaborating with Israel’s leading research labs and medical centers, and commercializing its resulting innovative and proprietary products in leading international markets, focusing initially on the strong medical cannabis market in Canada.